Navigation Links
In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharma Division
Date:5/19/2009

WOODMERE, N.Y., May 19 /PRNewswire/ -- In an eleventh-hour attempt to smear Ted Karkus, The Quigley Corporation (Nasdaq: QGLY) has issued a press release claiming that there was some improper financial arrangement between Dr. Richard Rosenbloom, a key staff member of a subsidiary of Quigley, and Mr. Ted Karkus, who leads a group of dissident shareholders who have offered their own slate of Quigley's Board of Directors for election at the annual meeting scheduled for Wednesday, May 20, 2009.

Mr. Karkus had loaned Dr. Rosenbloom a total of $55,000 over a period of approximately six months. The loans were sought by Dr. Rosenbloom for personal purposes. They are reflected in a written promissory note that provides, appropriately, for repayment of the loan and the payment of interest, and are secured by other assets of Dr. Rosenbloom.

Mr. Karkus did not seek, nor did he receive, any "inside information" in connection with the loan or otherwise.

Mr. Karkus has stated: "I am proud to have been in a position to help out someone in need. For the Company to attempt to manufacture a scandal on the last day of voting is disgraceful. It is quite obvious that they knew about this loan before today, and for the Company to treat Richard Rosenbloom so disgracefully is truly reprehensible."

Quigley has apparently determined to suspend, and perhaps discharge, Dr. Rosenbloom as a result of his alleged failure to report the loans to the CEO, Mr. Guy Quigley. Putting aside the question of what right Mr. Guy Quigley had to demand reports of this kind, the willingness of The Quigley Corporation to sacrifice Dr. Rosenbloom in an effort to impugn Mr. Karkus must be of grave concern to all shareholders. As the Company just stated in its Form 10-K, filed on March 9, 2009:

        The Company's Future Success Depends on the Continued Employment of
        Richard A. Rosenbloom, M.D., Ph.D., with Pharma.  Pharma's potential
        new products are being developed through the efforts of Dr.
        Rosenbloom.  The loss of his services could have a material adverse
        effect on the Company's product development and future operations.

In short, Mr. Guy Quigley is willing to subject your Company to this possible material adverse effect and to jeopardize the Company's product development and future operations, all in the name of avoiding a loss of control.

Quigley has loosely alluded to discovery responses made by Mr. Ted Karkus in recent litigation that Quigley began against him and other members of the his group (but, notably, that Quigley has since voluntarily abandoned). The Company's discovery was focused on officers and directors of The Quigley Corporation. Dr. Rosenbloom is neither an officer nor director of the Quigley Corporation and instead is on the staff of a wholly-owned subsidiary. Whatever else may be made of the record of the now-dismissed action, there is no proper basis for any claim of impropriety.

Unfortunately, the entire affair reveals the lengths that entrenched management will go, and the injury they are willing to inflict on both a key staff member of the Pharma subsidiary and the Company's overall interests, in order to stay in office.

The Karkus group respectively urges the shareholders to replace the Board of Directors on May 20, 2009, and elect directors that will put the interests of the Company and its shareholders first.

VOTING INSTRUCTIONS:

Only your last vote counts. Simply find the control # on our lightly shaded Blue Voting Instruction Form. This is the voting form that has the Ted Karkus list of Shareholder Nominees on it. Then call (800) 454-8683 or go to www.proxyvote.com and input your control # when prompted. It is that simple to vote or to change your vote.

You may also call the Shareholder Nominees' proxy solicitor, The Altman Group, toll free at (866) 796-7175, if you have any questions or need assistance. Finally, Mr. Karkus welcomes all calls to discuss the Company and its future with any or shareholders. He is available at (516) 569-9999.

Important Additional Information

Ted Karkus, Mark Burnett, John DeShazo, Mark Frank, Louis Gleckel, MD, Mark Leventhal and James McCubbin (the "Shareholder Nominees") filed a definitive proxy statement with the Securities and Exchange Commission (the "SEC") on May 1, 2009 in connection with the 2009 Annual Meeting of Stockholders of The Quigley Corporation. Stockholders are strongly advised to read the Shareholder Nominees' proxy statement as it contains important information. Stockholders may obtain an additional copy of the Shareholder Nominee's definitive proxy statement and any other documents filed by them with the SEC for free at the SEC's website at http://www.sec.gov. Additionally, copies of the definitive proxy statement are available for free at www.shareholdermaterial.com/qgly.


'/>"/>
SOURCE Ted Karkus
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future
2. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
3. Boston Scientific to Donate Cardiac Rhythm Management Devices to Heartbeat International for Implantation in Needy Patients
4. Medical Simulation Corporation to Introduce Central Line Management Program at the National Teaching Institute and Critical Care Exposition
5. Sixth Annual Healthcare Unbound Conference to Focus on Remote Monitoring, Home Telehealth & eHealth for Chronic Care Management & Wellness Promotion
6. GenomeQuest, Inc. Announces Digital Gene Expression Solution Within Its Sequence Data Management Platform
7. BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management
8. GenVault Corporation Launches its Latest Centralized and Standardized Software Solution for Biobanking and Biological Sample Management, GenConnect 3.2
9. Bio-Optronics Adds Innovative Electronic Data Capture (EDC) Solution to Clinical Conductor Clinical Trial Management System (CTMS), Continues to Improve Workflow and Productivity
10. US Oncology Provides Full Service Management of Clinical Trials
11. NexGen Biofuels Ltd Signs Letter of Intent for the Purchase of World Venture Management, Inc. Assets and the Sale of its Current Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016 Australian-US drug discovery and ... today the appointment of a new Chairman, Mr John ... , effective immediately. James Garner , has ... Director and former Acting CEO, Mr Iain Ross , ... Director. --> James Garner , has also been ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... Club, takes place February 5-6 at the University’s student center, Kehr Union, ... such as workshops and competitions for ample networking, learning and collaborating opportunities. ...
(Date:2/4/2016)... N.J. , Feb. 4, 2016 ContraVir ... focused on the development and commercialization of targeted antiviral ... CEO & Investor Conference 2016, to be held February ... Source Capital Group,s 2016 Disruptive Growth & Healthcare Conference, ... on February 10-11, 2016. James Sapirstein , ...
(Date:2/4/2016)... Brooklyn, NY (PRWEB) , ... February 04, 2016 , ... ... cuvettes for over 10 years. What sets them apart from other cuvette ... that is posted on their website. On top of this steady flow of ...
Breaking Biology Technology:
(Date:1/25/2016)... SEATTLE , Jan. 25, 2016  Glencoe Software, ... biotech, pharma and publication industries, will provide the data ... Phenotypic Screening Centre (NPSC). ... Phenotypic analysis ... even whole organisms, allowing comparisons between states such as ...
(Date:1/22/2016)... 22, 2016 ... the "Global Biometrics Market in Retail ... --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has ... Biometrics Market in Retail Sector 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ) ...
(Date:1/20/2016)... A market that just keeps on growing. Molecular Diagnostics ... genomics knowledge. Learn all about it in this new ... trends are pushing market growth and company valuations. Trends ... pathogen evolution - next generation sequencing - emergence of ... the role of genetic material in Disease and Health ...
Breaking Biology News(10 mins):